On Monday, March 10, Lupin’s stock jumped more than 2.5 percent after the US FDA gave the business the final approval to introduce Rivaroxaban tablets USP to the US market. Lupin reported that Rivaroxaban Tablets USP, 2.5 mg, has projected yearly sales of $446 million in the US in an exchange filing dated March 7. The medication is a bioequivalency to Janssen Pharmaceuticals, Inc.’s 2.5 mg Xarelto Tablets. Patients with peripheral artery disease (PAD), particularly those who have recently undergone lower extremity revascularization as a result of symptomatic PAD, can utilize it to lessen their risk of major cardiovascular events and significant thrombotic vascular events. The pharmaceutical giant’s shares were up 0.39% at ₹2,038 at 10:14 AM on the National Stock Exchange (NSE). 93,043.04 crore is its market capitalization.
On January 2, 2025, the firm reached its 52-week high of ₹2,402.90. Since February 10, the stock has fallen more than 6% in the past month. Over the course of six months, the stock had dropped 8.31%. The share price of Lupin has dropped 13.87% so far this year. However, after March 11, 2024, it has increased by 21.5% in a year. Citi, a worldwide brokerage business, recently upgraded the company based on its predictions of new launches for the US market and continued margin strength.
December quarter results Compared to the equivalent quarter of the previous fiscal year, when it recorded ₹618.7 crore, Lupin reported a 38.8% increase in its consolidated net profit or profit after tax (PAT) for the December quarter (Q3 FY25) at ₹858.9 crore. Sales for the reviewed quarter was ₹5,618.6 crore, a 10.6% increase over the ₹5,079.9 crore recorded in the December 2023 quarter. Go deeper. Profits before interest, taxes, depreciation, and amortization, or EBITDA, increased by 32.1% to ₹1,409.6 crore. It was ₹1,067.3 crore in the prior fiscal year’s equivalent quarter. As a global pharmaceutical corporation, Lupin creates and markets pharmaceuticals, biotechnology products, and APIs. The company’s main office is in Mumbai, India. Lupin focuses on anti-tuberculosis, diabetes, asthma, and anti-infectives.